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Background: To investigate the outcome and prognostic factors for corneal graft recovery after severe corneal
graft rejection following penetrating keratoplasty (PKP) treated with topical and systemic steroids.
Methods: Fifty-eight eyes in 58 patients with severe corneal graft rejection following PKP were treated with topical
and systemic steroids. Factors affecting the reversibility and maintenance of graft transparency were analyzed.
Results: Graft transparency was restored in 37 of 58 eyes (63.8%). Clarity of the graft was maintained in 25 of 37
eyes after transparency was restored, while corneal decompensation developed at a mean of 6.0 ± 4.3 months in
the remainder. The interval between rejection and treatment with systemic steroids was shorter in cases that
recovered graft transparency (OR, 0.88, 95% CI. 0.80–0.97, P = 0.0093). Corneal decompensation after the recovery of
corneal transparency tend to occur in cases of regraft (OR, 0.09, 95% CI. 0.01–0.54, P = 0.0091).
Conclusions: Severe corneal graft rejection after PKP was reversible in approximately two-thirds of the cases, with
graft transparency being maintained in two-thirds of them when treated with both topical and systemic steroids.
Early treatment confers a benefit in terms of the recovery of graft transparency.
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Corneal graft rejection is a severe complication that can
follow penetrating keratoplasty (PKP), possibly leading
to severe endothelial cell loss and corneal decompensa-
tion [1,2]. Risk factors for corneal graft rejection include
donor age, graft size, repeated grafts, previous episodes
of graft rejection, and corneal vascularisation [3-6]. Al-
though the prognosis of corneal graft rejection has been
reported [7-9], the severity of rejection varies and treat-
ment has not been standardised in those studies. Graft
rejection was treated with topical steroids with or with-
out systemic steroids according to the severity of rejec-
tion or physicians choice [7-9]. Moreover, there is
limited information on the influence of preoperative
endothelial cell density before rejection on prognosis,* Correspondence: kyamazoe1528@yahoo.co.jp
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reproduction in any medium, provided the orand factors affecting corneal decompensation after the
recovery of corneal transparency.
This study investigated the outcome in severe corneal
graft rejection treated with a standardised protocol in-
cluding topical and systemic steroids and factors
affecting the reversibility and maintenance of graft
transparency.Methods
Patients and examination
We retrospectively studied 58 eyes in 58 patients who
developed severe corneal graft rejection following PKP
and were treated with topical and systemic steroids at
Tokyo Dental College Ichikawa General Hospital be-
tween January 2005 and December 2010. Only patients
with severe endothelial rejection defined as severe graft
edema with an endothelial rejection line or five or more
keratic precipitates appearing after attaining postoperative
graft transparency were enrolled. All patients were
hospitalised. Patients with a follow-up period of less thanal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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density (ECD) was measured using the EM-3000 (Tomey,
Nagoya, Japan), and the value measured within 1 year be-
fore or after graft rejection were assessed. This study was
conducted in accordance with the tenets of the Declar-
ation of Helsinki and approval was obtained from ethics
committees at our institution. All patients provided writ-
ten informed consent for treatment with topical and sys-
temic steroids.
Treatment protocols
Postoperatively, the patients received medication with top-
ical steroid to prevent graft rejection, according to the
following protocol. Dexametasone phosphate 0.1% was
administered five times daily and tapered over a period of
6 months, and fluorometholone 0.1% was continued unless
infection or an uncontrollable increase in IOP occurred.
All patients diagnosed with graft rejection were treated
with topical and systemic steroids. Dexamethasone phos-
phate 0.1% hourly was commenced immediately after
diagnosis of a rejection and tapered according to the clin-
ical response over several weeks. Treatment with systemic
steroids was started in a few days after diagnosis of a rejec-
tion with intravenous dexamethasone phosphate or
methylprednisolone. In the former, 8 mg/day dexametha-
sone phosphate was administered for 3 days, after which it
was tapered to 6 mg/day for 3 days and 4 mg/day for 3 -
days. In the latter, 500 mg/day methylprednisolone was
administered for 3 days, followed by oral 2 mg/day dexa-
methasone phosphate, which was then tapered over 2 -
weeks. Patients over 70 years old were given half of the
steroid dose. Patients with a systemic disease, including
infection, gastric ulcer and poorly controlled diabetes
mellitus, were not treated with this protocol and not
included in this study.
Outcome measures
The main outcome measure was the rate of reversibility of
corneal graft rejection. Rejection was considered reversible
when the clinical signs had disappeared after treatment.
The patients were divided into two groups: cases in which
transparency was (Group 1) and was not (Group 2)
restored. Parameters of interest included age, sex, diagnosis
before PKP, type of surgery, history of glaucoma, previous
episodes of rejection, ECD before corneal graft rejection,
the interval between PKP and rejection, type of systemic
steroid treatment and interval between rejection and treat-
ment with systemic steroids. These factors were assessed
and compared between Groups 1 and 2. In Group 1, the
interval between treatment and the recovery of transpar-
ency, and whether transparency was maintained over the
observation period, were also assessed. Cases in which
transparency was maintained after recovery from rejection
(Group 1A, n = 25) and cases wherein decompensationoccurred after transparency was recovered (Group 1B, n =
12) were also compared.
Statistical analysis
Statistically significant differences between the two groups
were determined using logistic regression. A P-value of <0.01
was considered statistically significant. All statistical analyses
were performedwith SSRI software (SSRI,Tokyo, Japan).
Results
Demographics and clinical features
The patient demographics are shown in Table 1. The
topical steroid that had been administered before rejec-
tion to prevent rejection was dexamethasone phosphate
0.1% in 25 cases, fluorometholone 0.1% in 19 cases and
cyclosporine 0.1% in two cases. No steroid treatment
had been administered before rejection in nine cases, in-
cluding seven cases at a physician’s direction several
years after surgery and two eyes against a physician’s
recommendation. No data were available in three add-
itional cases. The factor triggering rejection was related
to broken sutures in five cases and self-discontinuation
of topical steroid treatment in two cases. The mean
interval between PKP and corneal graft rejection was
31.5 ± 36.7 months and that between corneal graft rejec-
tion and the administration of systemic steroids was 9.2
± 9.7 days. All patients were treated for corneal graft re-
jection with above protocol, which is started with dexa-
methasone phosphate 0.1% eye drop and systemic
steroids. The mean average follow-up after corneal graft
rejection was 19.8 ± 12.7 months.
Outcome of steroid treatment
The mean best-corrected visual acuity (Log MAR) was
0.66 ± 0.75 before corneal graft rejection, 1.33 ± 0.87 be-
fore treating the corneal graft rejection and 1.03 ± 1.04
after treatment. Data on the ECD before rejection were
obtained in 29 eyes (50.0%). In 18 of these eyes, data on
the ECD after rejection were also obtained. The ECD in
18 eyes was 1556 ± 840 cells/mm2 before rejection versus
772 ± 464 cells/mm2 after rejection (P < 0.001). Graft
transparency was restored in 37 of 58 eyes (63.8%).
Nineteen of 41 cases that were observed for more than
1 year after rejection had a clear graft at 1 year and 4 of
7 cases that were observed for more than 3 years after
rejection had a clear graft at 3 years. Graft clarity was
maintained in 25 of 37 eyes (observation period, 20.7 ±
14.4 months), with corneal decompensation occurring
6.0 ± 4.3 months after the recovery of transparency in
the remainder.
Prognostic factors
Groups 1 and 2 are compared in Table 2. The interval
between rejection and treatment was shorter in Group 1
Table 1 Patient demographics
N % Mean ± SD





Bullous keratopathy 21 36.2
Regraft 14 24.1
Corneal scar 13 22.4
Corneal dystrophy 4 6.9
Keratoconus 3 5.2
Corneal ulcer 3 5.2
Type of surgery
PKP 43 74.1
PKP + ECCE + IOL 13 22.4
PKP + IOL suture 2 3.4
history of glaucoma 17 29.3
Previous episodes of rejection 8 13.8
ECD before rejection 1401 ± 776
Interval between PKP and rejection (months) 31.5 ± 36.7
Interval between rejection and treatment with systemic steroids (days) 9.2 ± 9.7
Systemic steroid
Dexamethasone phosphate 47 81.0
Methylprednisolone 11 19.0
Complications
Elevated IOP 15 25.9
Herpes simplex keratitis 3 5.2
Fungal keratitis 1 1.7
ECCE, extracapsular cataract extraction; ECD, endothelial cell density; IOL, intraocular lens; IOP, intraocular pressure; PKP, penetrating keratoplasty; SD,
standard deviation.
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were observed in age, sex, diagnosis before PKP, type of
surgery, history of glaucoma, previous episodes of rejec-
tion, ECD before rejection, interval between PKP and re-
jection or treatment method.
Groups 1A and 1B are compared in Table 3. Regarding
the diagnosis before PKP, regraft was less prevalent in
Group 1A (OR, 0.09, 95% CI, 0.01–0.54, P = 0.091). No
differences were observed in age, sex, type of surgery,
history of glaucoma, previous rejection episodes, ECD
before rejection, interval between rejection and treat-
ment, treatment or interval between treatment and re-
covery of transparency.
Side effects of steroids
The side effects of topical and systemic steroids are
shown in Table 1. Increased intraocular pressure (IOP),
which was controlled with additional medication, wasdetected in 15 of 58 eyes (25.9%). Seven of the 15
patients had pre-existing glaucoma. Corneal infection
developed within 3 months in 4 of 58 eyes (6.9%), in-
cluding three cases of recurrent herpes simplex keratitis
and one of fungal keratitis. No severe systemic side
effects were observed and intravenous steroid adminis-
tration was completed according to the protocol in all
cases.
Discussion
Severe endothelial rejection was treated with topical and
systemic steroids in all cases and the rate of reversibility
was 63.8%. The rate of reversibility was reported to be
51–63.3% in previous studies [7,8]. Wagoner et al.
investigated 152 cases of severe endothelial rejection
following PKP treated with topical steroids with or with-
out systemic steroids and reported that graft survival
was 42.6% at 1 year and 36.1% at 3 years [9]. Although
Table 2 Comparison of the clinical characteristics between Group 1 (cases in which transparency was restored, n = 37)
and Group 2 (cases in which transparency was not restored, n = 21)
Group 1 Group 2 OR P-value
mean ± SD mean ± SD (95% CI)
n (%) n (%)
Age (years) 59.4 ± 15.5 68.3 ± 12.5 0.95 (0.91–1.00) 0.037
Sex
Male 23 (62.2) 10 (47.6) 1.81 (0.61–5.34) 0.28
Female 14 (37.8) 11 (52.4) 1.00
Diagnosis before PKP
Bullous keratopathy 13 (35.1) 8 (38.1) 0.88 (0.29–2.67) 0.82
Regraft 8 (21.6) 6 (28.6) 0.69 (0.20–2.36) 0.55
Corneal scar 9 (24.3) 4 (19.0) 1.37 (0.36–5.13) 0.64
Corneal dystrophy 3 (8.1) 1 (4.8) 1.76 (0.17–18.13) 0.63
Keratoconus 3 (8.1) 0 (0.0) – 1.00
Corneal ulcer 1 (2.7) 2 (9.5) 0.26 (0.02–3.10) 0.29
Type of surgery
PKP 27 (73.0) 16 (76.2) 0.84 (0.24–2.91) 0.79
PKP + ECCE + IOL 9 (24.3) 4 (19.0) 1.37 (0.36–5.13) 0.64
PKP + IOL suture 1 (2.7) 1 (4.8) 0.56 (0.03–9.37) 0.68
history of glaucoma 8 (21.6) 9 (42.9) 0.37 (0.11-1.18) 0.093
Previous episodes of rejection 4 (10.8) 4 (19.0) 0.51 (0.11–2.32) 0.38
ECD before rejection 1669 ± 747 806 ± 455 1.002 (1.001–1.004) 0.013
Interval between PKP and rejection (months) 33.3 ± 40.0 28.2 ± 30.7 1.00 (0.99–1.02) 0.61
Interval between rejection and treatment with systemic steroids (days) 6.2 ± 5.6 14.5 ± 12.8 0.88 (0.80–0.97) 0.0093
Systemic steroid
Dexamethasone phosphate 29 (78.4) 18 (85.7) 0.60 (0.14–2.58) 0.50
Methylprednisolone 8 (21.6) 3 (14.3) 1.66 (0.39–7.07)
ECCE, extracapsular cataract extraction; ECD, endothelial cell density; IOL, intraocular lens; PKP, penetrating keratoplasty; SD, standard deviation.
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existed among other factors, the effectiveness of our
treatment regimen in severe cases was comparable with
that of earlier report. Our results suggest additional sys-
temic steroids provide similar effective outcomes even in
severe cases with severe edema. However, it is difficult
to compare the status of patients before treatment with
previous reports rigorously, and further study is needed.
No serious systemic side effects were observed because
we excluded patients in poor general health. Careful ob-
servation to detect elevated IOP and infection, especially
herpes simplex or fungal keratitis, is necessary when
treating patients with topical or systemic steroids.
In this study, a longer interval between corneal graft
rejection and treatment with systemic steroids was
associated with an increased risk of corneal decompen-
sation after graft rejection. Risk factors for irreversibility
after graft rejection reported in previous studies included
donor age, patient age, diagnosis of BK, history of rejec-
tion or graft failure episodes [7,9]. Early treatment wasreported to be associated with a better outcome [10] and
our results support this finding. Factors affecting corneal
decompensation after the recovery of corneal transpar-
ency were also investigated. Corneal decompensation
occurs in one-third of the cases within approximately 6 -
months. A comparison of these cases with those in which
corneal transparency was maintained revealed that regraft
as a diagnosis before previous PKP was more frequent in
the former. Notably, this factor was not associated with
graft reversibility of transparency, and factor affecting
graft reversibility of transparency was not associated with
the maintenance of graft transparency. In regraft cases,
more careful observation is needed after corneal transpar-
ency has been restored.
The endothelial cell density decreased significantly
after corneal graft rejection. Musch et al. reported that
the ECD decreased by 11.8% [11], while we observed a
reduction in ECD in 18 cases in which ECD was
determined before and after corneal graft rejection for a
rate of 50.4%, which was much higher than that in
Table 3 Comparison of the clinical characteristics between Group 1A (cases in which transparency was maintained
after recovery from rejection, n = 25) and Group 1B (cases in which the decompensation occurring after transparency
recovered, n = 12)
Group 1A Group 1B OR P-Value
mean ± SD mean ± SD (95% CI)
n (%) n (%)
Age (years) 58.4 ± 17.4 61.5 ± 10.8 0.99 (0.94–1.03) 0.57
Sex
Male 17 (68.0) 6 (50.0) 2.13 (0.52–8.70) 0.29
Female 8 (32.0) 6 (50.0)
Diagnosis before previous PKP
Bullous keratopathy 8 (32.0) 5 (41.7) 0.66 (0.16–2.73) 0.57
Regraft 2 (8.0) 6 (50.0) 0.09 (0.01–0.54) 0.0091
Corneal scarring 8 (32.0) 1 (8.3) 5.18 (0.57–47.32) 0.14
Corneal dystrophy 3 (12.0) 0 (0.0) – 1.00
Keratoconus 3 (12.0) 0 (0.0) – 1.00
Corneal ulcer 1 (4.0) 0 (0.0) – 1.00
Type of surgery
PKP 17 ((68.0) 10 (83.3) 0.43 (0.08–2.41) 0.33
PKP + ECCE + IOL 7 (28.0) 2 (16.7) 1.94 (0.34–11.20) 0.46
PKP + IOL suture 1 (4.0) 0 (0.0) – 1.00
history of glaucoma 5 (20.0) 3 (25.0) 0.75 (0.15-3.84) 0.73
Previous episodes of rejection 1 (4.0) 4 (33.3) 0.13 (0.01–1.36) 0.09
ECD before rejection 1523 ± 666 2010 ± 876 0.999 (0.998–1.001) 0.19
Interval between PKP and rejection (months) 41.3 ± 44.2 16.8 ± 23.3 1.03 (0.99–1.06) 0.12
Interval between rejection and treatment with systemic steroids (days) 6.5 ± 5.5 5.8 ± 6.1 1.02 (0.89–1.15) 0.80
Systemic steroid
Dexamethasone phosphate 20 (80.0) 9 (75.0) 1.33 (0.26–6.83) 0.73
Methylprednisolone 5 (20.0) 3 (25.0) 0.75 (0.15–3.84) 0.73
Interval between treatment and recovery of transparency (days) 72.5 ± 70.4 93.0 ± 208.0 0.999 (0.994–1.004) 0.65
ECCE, extracapsular cataract extraction; ECD, endothelial cell density; IOL, intraocular lens; PKP, penetrating keratoplasty; SD, standard deviation.
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could be calculated, indicating the absence of severe
edema, were believed to be mild cases compared with
cases in which ECD could not be calculated in our
study. Therefore, the endothelial cell loss may have been
underestimated. These indicate the greater incidence of
severe cases of rejection in our study compared with
previously reported series [11]. Our results suggest the
importance of preventing rejection, as well as close
monitoring and appropriate and aggressive management
of rejection when it occurs.
The interval between PKP and corneal graft rejection
was 31.5 ± 36.7 months, which was longer than that in
previous studies, including 15.4 ± 20.9, 10.4 ± 9.3 and
15.3 ± 14.4 months reported respectively by Epstein
et al. [4], Naacke et al. [7] and Sangwan et al. [9]. One
reason for this discrepancy between our results andthose of these earlier studies may be that topical steroid
treatment after PKP tended to be continued longer in
our patients. In fact, we recently reported the efficacy of
prolonged use of topical steroids for the prevention of
rejection after PKP [12]. If no side effects are observed,
such as elevated IOP, cataracts or infection, the long-
term use of topical steroids is recommended.
Conclusions
This study demonstrated that severe rejection was revers-
ible in two-thirds of the cases reviewed, with graft trans-
parency being maintained in two-thirds of them. A longer
interval between corneal graft rejection and treatment was
associated with an increased risk of corneal decompensa-
tion after graft rejection. Regraft as a diagnosis before pre-
vious PKP was associated with corneal decompensation
after the recovery of corneal transparency.
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